Pfizer's Forgotten Cancer Pill Is About to Become Its Next Blockbuster

Pfizer (NYSE: PFE) had big expectations for Inlyta when it launched in 2012. Over the past few years, though, it's fallen out of favor as new, more effective treatments set up camp in its neighborhood.